Focus Partners Advisor Solutions LLC Makes New Investment in United Therapeutics Corporation $UTHR

Focus Partners Advisor Solutions LLC bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, Holdings Channel.com reports. The fund bought 1,440 shares of the biotechnology company’s stock, valued at approximately $414,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Chung Wu Investment Group LLC acquired a new position in United Therapeutics during the 2nd quarter worth approximately $29,000. SVB Wealth LLC purchased a new position in United Therapeutics in the first quarter valued at about $32,000. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 85 shares in the last quarter. Brooklyn Investment Group increased its holdings in United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after buying an additional 98 shares in the last quarter. Finally, WPG Advisers LLC purchased a new position in United Therapeutics in the first quarter valued at about $60,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on UTHR. Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a report on Wednesday. Bank of America raised their price objective on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research note on Thursday. Weiss Ratings reissued a “hold (c+)” rating on shares of United Therapeutics in a research note on Wednesday, October 8th. Finally, Morgan Stanley set a $447.00 price objective on shares of United Therapeutics in a research note on Wednesday. Seven equities research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $483.73.

Insider Buying and Selling

In other United Therapeutics news, CEO Martine A. Rothblatt sold 4,000 shares of United Therapeutics stock in a transaction on Monday, October 27th. The shares were sold at an average price of $415.54, for a total value of $1,662,160.00. Following the transaction, the chief executive officer owned 130 shares in the company, valued at $54,020.20. This trade represents a 96.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Paul A. Mahon sold 11,000 shares of United Therapeutics stock in a transaction on Thursday, October 30th. The shares were sold at an average price of $450.34, for a total transaction of $4,953,740.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $16,563,955.54. This trade represents a 23.02% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 364,435 shares of company stock worth $151,067,172. 10.30% of the stock is owned by insiders.

United Therapeutics Stock Performance

Shares of NASDAQ UTHR opened at $453.53 on Friday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $479.50. The firm’s 50 day moving average price is $407.40 and its 200 day moving average price is $336.86. The firm has a market cap of $20.46 billion, a P/E ratio of 17.19, a price-to-earnings-growth ratio of 4.96 and a beta of 0.66.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The firm had revenue of $799.50 million for the quarter, compared to analyst estimates of $812.87 million. During the same quarter last year, the business earned $6.39 earnings per share. United Therapeutics’s revenue was up 6.8% compared to the same quarter last year. As a group, equities analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.